ECE2017 Eposter Presentations: Thyroid Thyroid (non-cancer) (260 abstracts)
Metastatic differentiated thyroid carcinoma: cumulative doses of adjunct 131i-iodide therapy
Patrícia Gouveia 1 , Teresa Pereira 2 , Ana Amado 2 , Ricardo Teixeira 1 , Antonio Costa 3 , André Carvalho 2 , Cláudia Freitas 2 & Fátima Borges 2
1Department of Nuclear Medicine, Centro Hospitalar do Porto, Porto, Portugal; 2Department of Endocrinology, Centro Hospitalar do Porto, Porto, Portugal; 3Department of Surgery 2, Centro Hospitalar do Porto, Porto, Portugal.
Introduction: 131I-iodide therapy (RIT) is an important treatment modality for patients with differentiated thyroid carcinoma (DTC). However, despite the overall excellent outcome, some DTC patients with poor prognosis may require multiple doses of radioactive iodine.
Aim: The purpose of our study was to evaluate the efficacy of cumulative doses (CDs) of RIT in metastatic DTC patients.
Material and methods: A retrospective study was conducted on a cohort of 84 metastatic DTC patients (mean age 46.6±17.4 years) who received a CDs ≥300 mCi of RIT, between January 1956 and December 2016. A disease-free status was established as: undetectable TSH-suppressed Thyroglobulin levels, whole body imaging scan without local-regional uptake or distant metastases and negative cervical ultrasound or thoracic CT scan.
Results: Eighty-four patients, 58 females and 26 males, who completed more than one RIT with a CD ≥300 mCi, were followed up for 15.0±8.8 years. At the time of diagnosis 62 (73.8%) patients had local cervical metastases and 22 (26.2%) had distant metastases. Papillary carcinoma sub-type was present in 75 (89.3%) of patients. Seventeen out of 84 patients (20.2%) achieved a disease-free status. No patient with CDs higher of 450mCi has reached a disease-free status. Patients with evidence of brain or bone metastases (7 out of 94) did not achieve the disease-free status, regardless of the CDs received.
Conclusion: Twenty percent of patients who received a CDs ≥300 mCi of RIT achieved a disease-free status. Quality of life and the disease progression rate are important aspects that were not addressed in our study. The decision of further treatment with RIT should be carefully evaluated and made on a case-by-case basis. Furthermore, this study seems to indicate that brain or bone metastases may not respond to higher CDs.
Article tools
My recent searches
My recently viewed abstracts
Authors
Endocrine Abstracts
ISSN 1470-3947 (print) | ISSN 1479-6848 (online)
© Bioscientifica 2024 |
Privacy policy |
Cookie settings
BiosciAbstracts
Bioscientifica Abstracts is the gateway to a series of products that provide a permanent, citable record of abstracts for biomedical and life science conferences.
Find out more